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Modulation of vascular cell growth
kinetics by local cytokine delivery from
fibrin glue suspensions
Paula K. Shireman, MD, Brian Hampton, Wilson H. Burgess, PhD, and
Howard P. Greisler, MD, Maywood, Ill
Purpose: Fibrin glue (FG) has been used as a delivery system for bioactive agents on
grafts and angioplasty sites. Reports from two different institutions suggest that heparin
concentrations of 500 U/mL in FG inhibit smooth muscle cell (SMC) proliferation, but
do not effect endothelial cell (EC) proliferation. The purposes of this study were to (1)
quantify the diffusive release of fibroblast growth factor-1 (FGF-1) and heparin from
FG; (2) determine the effect of heparin and FGF-1 on SMC proliferation when the cells
are immediately plated on the FG; and (3) by means of the diffusive release data, design
a new in vitro model that may differentiate the effect of FG-incorporated FGF-1 and
heparin, rather than the released, solubilized components of these two factors, on SMC
and EC proliferation.
Methods: 125I-FGF-1 or 3H-heparin release from FG into the overlying media was mea-
sured serially in a 96-hour period, either with or without cells. SMCs were immediate-
ly plated on FG containing various concentrations of FGF-1 and heparin. SMCs or ECs
were plated on identical groups of FG containing FGF-1 and heparin 24 hours after the
FG was made to exclude the effect on cell growth of the initial release of FGF-1 into the
media.
Results: In the first 24 hours, 70% ± 1% of the FGF-1 and 59% ± 2% of the heparin in
the FG was released into the overlying media, with minimal release occurring thereafter.
The cell type or absence of cells did not affect release, but there was five times more
FGF-1 and four times more heparin in the media at 72 hours for the immediate plating
versus the delayed plating because of a diffusive release primarily in the first 24 hours. 
A heparin concentration of 500 U/mL inhibited SMC proliferation, as compared with
5 U/mL heparin, only when immediate plating of SMCs was used. Comparing imme-
diate versus delayed SMC plating, at equivalent FGF-1 and heparin doses, immediate
plating induced greater proliferation than delayed plating; this was likely caused by the
higher soluble FGF-1 concentration. Heparin doses as high as 500 U/mL had little
effect on SMC proliferation. In contrast, ECs died with delayed plating on FG contain-
ing 500 U/mL heparin, and their growth was inhibited at 50 U/mL heparin, as com-
pared with 5 U/mL heparin.
Conclusion: The differences in SMC proliferation when comparing immediate versus
delayed plating are likely caused by diffusive release of heparin and FGF-1 into the
media. Our ongoing work uses an optimized in vitro FG system that minimizes the
effects of soluble factors. This is an important distinction, because the cytokines that are
released in vivo will be removed by blood flow and, thus, may not exert an effect unless
they are contained within the FG. (J Vasc Surg 1999;29:852-62.)
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The treatment of arterial occlusive disease leads
to 550,000 vascular bypass grafting procedures and
500,000 carotid endarterectomies annually in the
United States.1,2 These procedures damage the
endothelial lining of the blood vessels, often leading
to thrombosis and intimal hyperplasia. Clinically,
endothelial cell (EC) resurfacing of vascular grafts or
of long segments of de-endothelialized arteries after
endarterectomy or angioplasty does not occur. This
has led many researchers to try and develop ways to
replace the damaged EC lining.
One of these strategies involves fibrin glue (FG).
FG has been used experimentally as an extended
delivery system for cytokines on vascular grafts and
angioplasty sites. Cytokines and heparin can be
mixed with fibrinogen before the addition of throm-
bin. Thrombin cleaves the fibrinogen into fibrin,
and a matrix is created that contains the cytokines
and heparin. We believe that FG acts as a passive
reservoir for the cytokines, but formal binding stud-
ies have not been performed. The body’s fibrinolyt-
ic system slowly degrades the matrix, possibly releas-
ing the cytokines. 
Our group has previously reported a FG system
containing fibroblast growth factor-1 (FGF-1), also
known as acidic FGF, and heparin used on grafts
implanted into the aortoiliac and thoracoabdominal
aortic positions in dogs.3,4 Expanded polytetrafluo-
roethylene (ePTFE) grafts were treated with FG
containing 1 ng/cm2 FGF-1 and 20 m g/cm2
heparin. Control grafts were either untreated or
treated with FG containing heparin but not FGF-1.
The grafts treated with FGF-1/heparin/FG devel-
oped a significantly greater luminal cell mitotic index
and complete EC coverage by 4 weeks, which was
never seen in the explants of the control group of
the canine aortoiliac grafts.3 Similar results were
reported with thoracoabdominal ePTFE-treated
grafts in the canine model studied after 20 weeks.4
Enhanced endothelial coverage of the graft was seen;
however, inner capsule thickness was significantly
greater in the FGF-1/heparin/FG group (139 ± 16
m m), as compared with either untreated grafts (67 ±
18 m m) or the FG-plus-heparin group (93 ± 9 m m).
FGF-1/heparin/FG–treated grafts also had an
increased cross-sectional mitotic index at 30 days, as
measured by means of tritiated thymidine incorpora-
tion, which returned to baseline levels at the 20-
week observation point.
FGF-1 stimulates both EC and smooth muscle
cell (SMC) proliferation. Concern about intimal
hyperplasia in the canine grafts receiving FGF-1 and
FG led to a series of studies designed to optimize the
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FGF-1 and heparin ratios in vitro.5 This optimiza-
tion was defined as maximizing EC proliferation
while minimizing SMC growth that may lead to inti-
mal hyperplasia. We attempted to achieve this by
manipulating the relative concentrations of heparin
in the FG. Heparin, a known inhibitor of SMC pro-
liferation, was added to the FG in increasing con-
centrations to determine the effect on EC and SMC
proliferation. Human umbilical vein endothelial cells
(HUVECs) or canine carotid artery SMCs were
grown on FG containing 10 ng/mL FGF-1 and
heparin concentrations of 0, 5, 50, or 500 U/mL,
and proliferation was measured with tritiated thymi-
dine incorporation. FG containing 10 ng/mL FGF-
1 but no heparin did not induce EC or SMC prolif-
eration higher than control levels (FG with no addi-
tives). This is presumably caused by thrombin
inactivation of FGF-1. The addition of heparin to
the FG protects the FGF-1 from thrombin inactiva-
tion. HUVEC proliferation was not affected by the
heparin concentrations of 5, 50, or 500 U/mL, but
canine carotid SMC proliferation was significantly
inhibited by the addition of 500 U/mL heparin.
Similar levels of SMC inhibition were also seen at a
heparin concentration of 250 U/mL. These in vitro
observations led us to conclude that the “optimal”
FG to induce EC, but not SMC, proliferation for
potential in vivo use would contain 10 ng/mL FGF-
1 and a heparin concentration of 250 U/mL or
higher.
This in vitro data5 led us to use FG with 10
ng/mL FGF-1 and 250 U/mL heparin in a canine
balloon-injury carotid model.6 We measured surface
re-endothelialization and were disappointed to find
no significant difference between the FG-treated
arteries and the negative controls that did not
receive FG treatment. The addition of cultured,
autologous, canine jugular vein endothelial cells to
the FG/FGF-1/heparin mixture did result in a sig-
nificant increase in surface reendothelialization than
did the FG treatment alone.
Another group, Weatherford et al,7 reported the
in vitro optimization of vascular endothelial growth
factor (VEGF) and heparin in FG. VEGF is a specif-
ic EC mitogen that does not induce SMC prolifera-
tion and thus would theoretically not have the dis-
advantage of increasing intimal hyperplasia. By using
human aortic ECs and SMCs grown on FG contain-
ing various concentrations of VEGF and heparin,
they also found that human EC proliferation was not
affected by heparin concentration and that SMC
proliferation was significantly inhibited by heparin in
a dose-dependent fashion in the FG. They conclud-
ed that the optimal FG contained 10 ng/mL VEGF
and 50 U/mL heparin.
These two in vitro studies5,7 plated ECs and
SMCs on the FG immediately after polymerization.
Cytokines and heparin are released by diffusion from
FG, and the soluble, released substances in the over-
lying media may affect cellular proliferation. In vivo,
released substances would be carried away by blood
flow and thus would not exert a local effect. In addi-
tion, species differences may exist in tissue culture
cell lines. We believed that these cytokine-release
issues may explain the disappointing results seen in
our canine balloon-injured carotid artery model,6
which used the in vitro optimized FG formulation.5
We decided to study the release of FGF-1 and
heparin in our in vitro model to determine whether
the released cytokines and heparin may account for
the SMC and EC proliferation effects demonstrated
in our previous paper.5 We hoped to reexamine our
in vitro model and perhaps change it to more accu-
rately reflect in vivo conditions. Therefore, we set
out to: (1) quantify the diffusive release of FGF-1
and heparin from FG; (2) determine the effect of
heparin and FGF-1 on SMC proliferation when the
cells are immediately plated on the FG; and (3) by
using the diffusive release data of FGF-1 and heparin
from FG, design a new in vitro model with delayed
plating of ECs and SMCs that may differentiate the
effect of FG-incorporated FGF-1 and heparin, rather
than the released, solubilized components of these
two factors, on SMC and EC proliferation.
METHODS
Animal care complied with “The Guide for the
Care and Use of Laboratory Animals” (Institute of
Laboratory Animal Resources, Commission on Life
Sciences, National Research Council, 1996) and the
“Principles of Laboratory Animal Care” (National
Institutes of Health publication no. 85-23, revised
1985).
Endothelial and smooth muscle cell harvest.
Adult, mongrel dogs were anesthetized with thio-
pental sodium (Abbott Laboratories, Morris Plains,
NJ), intubated, and ventilated. Anesthesia was main-
tained with nitrous oxide and halothane. Bilateral
neck incisions were made. For ECs, bilateral external
jugular veins were removed, inverted, and processed
per our previously reported protocol.6 In brief, the
veins were sequentially placed into 0.53 mmol/L
0.05% trypsin/ethylenediamine tetra-acetic acid
(EDTA; Gibco, Grand Island, NY) and 100 U/mL
collagenase (Gibco) at 37°C for 10 minutes each.
After discarding the veins, the trypsin and collage-
nase solutions were centrifuged at 1000 rpm for 10
minutes. The supernatants were discarded, and the
cells were suspended in 5 mL EC growth media (M-
199 [Gibco] supplemented with 10% fetal bovine
serum [FBS; Hyclone, Logan, Utah], 5 ng/mL
FGF-1 [American Red Cross, Rockville, Md], 5
U/mL bovine lung heparin [Pharmacia & Upjohn,
Kalamazoo, Mich], 100 U/mL penicillin, and 100
m g streptomycin [Gibco]). The ECs were plated onto
a fibronectin (American Red Cross) coated T-25 cul-
ture flask (2.5 m g/cm2) and incubated at 37°C in a
5% humidified CO2 chamber. The EC growth media
was changed every 2 to 3 days, and confluent cells
were passaged with trypsin-EDTA. EC identity was
confirmed by means of dual staining with factor VIII
(Dako, Carpenteria, Calif) and a -actin (Sigma
Chemical, St. Louis, Mo) antibody immunofluores-
cent staining. Only EC cultures exhibiting 95% or
more positive factor VIII staining and 5% or less pos-
itive a -actin staining were used for the proliferation
assays. ECs were used within passages 1 through 4.
SMCs were obtained from canine carotid arteries
with a previously published5 explant technique. In
brief, the carotid arteries were opened longitudinal-
ly, and the intima and adventitia were removed by
scraping and dissecting with a scalpel. The media
was minced and placed into SMC growth media
(Dulbecco’s modified Eagle’s media [DMEM] sup-
plemented with 10% FBS [Hyclone], 10 mmol/L L-
nonessential amino acids, 100 U/mL penicillin, 100
m g/mL streptomycin, 100 mmol/L L-sodium pyru-
vate, and 50 m g/mL gentamicin [all from Gibco]).
Primary SMCs migrating from the explants were
used in all experiments. SMC identity was confirmed
by means of immunofluorescent staining with a -
actin antibody (Sigma Chemical), and only cultures
exhibiting 95% or more positive staining were used
in the proliferation assays.
Fibrin glue plate preparation. FG was made
by reconstituting lyophilized human fibrinogen
(American Red Cross) prepared from donor-pooled
plasma with 0.9% saline. For modified FG, heparin
and FGF-1 were also added to obtain a solution with
a final concentration of 32 mg/mL fibrinogen,
FGF-1 at concentrations of 0, 10, 100, or 1000
ng/mL, and heparin at concentrations of 0, 5, 50,
or 500 U/mL. Lyophilized human thrombin
(American Red Cross) was reconstituted with 0.9%
saline and added to all solutions to make a final con-
centration of 0.32 U/mL. A solution containing fi-
brinogen and thrombin only was made and used as
the negative control. Before polymerization, the
solutions were pipetted in 30 m L aliquots into 96-
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well polystyrene plastic plates (Becton Dickinson,
Lincoln Park, NJ) and allowed to completely poly-
merize, about 1 hour, before placing cells, culture
media, or both into the wells.
Release of radioactive fibroblast growth fac-
tor-1 and heparin from fibrin glue. FG was made
as described, except 125I-FGF-1 (American Red
Cross) or 3H-heparin (NEN Life Sciences Products,
Boston, Mass) was added to the FG. The 125I-FGF-
1 was found to be more than 99% pure by means of
sodium dodecyl sulfate/polyacrylamide gel elec-
trophoresis and high-pressure liquid chromatogra-
phy. An 125I-FGF-1 concentration of 500 ng/mL
was chosen, because the specific activity of the 125I-
FGF-1 would allow detection of as low as 1% release
of FGF-1 into the media. A 500 ng/mL concentra-
tion of 125I-FGF-1 and heparin at a concentration of
5 or 500 U/mL were placed in the FG. After poly-
merization was complete, 200 m L of the EC or SMC
media, which were used in the proliferation assays,
was added to the wells. The media was removed at
the specified time and counted for radioactivity (1,4,
8, 24, 48, 72, and 96 hours), and there were 4 wells
per time point.
To measure heparin release, 3H-heparin was
placed in FG at a dose of 5 or 500 U/mL. Either 10
or 1000 ng/mL FGF-1 was also placed in the FG
with the 5 U/mL heparin to determine whether the
FGF-1 concentration affected heparin release.
Media was assayed at 4-, 24-, 48-, and 96-hour
points, and there were three replicate wells per time
point.
In addition, 30 m L of each FG solution was
pipetted into Ready Safe Scintillation Fluid
(Beckman Instruments, Fullerton, Calif) for 3H-
heparin or into tubes for gamma counting for 125I-
FGF-1 in replicates of 3 or 4, respectively. The aver-
age of the 30 m L FG samples represented the total
counts. Percent release of radio-labeled FGF-1 or
heparin was calculated by dividing the media counts
from each well by the average of the total FG counts
and multiplying by 100%. Data is expressed as the
mean percentage released plus or minus standard
deviation for each time point. 125I-FGF-1 or 3H-
heparin was not corrected for decay caused by the
short duration of the experiments, as compared with
the half-life of the isotopes (60 days and 12.5 years,
respectively).
For 125I-FGF-1, after counting the radioactivity
within the media samples, precipitation experiments
were performed to discriminate protein-bound ver-
sus free 125I. To each 200 m L media sample, 200 m L
0.1% bovine serum albumin (Sigma Chemical) and
100 m L 50% trichloroacetic acid (Sigma Chemical)
were added. The samples were incubated on ice for
30 minutes, and 1000 m L 10% trichloroacetic acid
was added. The samples were centrifuged at 4°C for
8 minutes at 5000 rpm, and the supernatant was
removed. The precipitate, which contained the 125I
that was bound to FGF-1, was counted and the per-
centage bound was calculated by dividing the pre-
cipitate counts by the media counts and multiplying
by 100%. The data are expressed as the mean per-
centage bound plus or minus standard deviation.
To assess whether the presence of cells affected
the release of substances from FG, ECs or SMCs
were plated on the FG 1 hour after polymerization
(immediate plating) or after removing and replacing
media that had been in contact with the FG for 24
hours before cell plating (delayed plating). Cells
were plated at 5000 cells per well and allowed to
grow for 72 hours before removing the media for
counting. Identical wells of FG had media only
placed on them in either an immediate or a delayed
fashion as controls.
Endothelial cell and smooth muscle cell pro-
liferation assays. Confluent cells were trypsinized
and plated on FG at 5000 cells/well in 200 m L of
media. Preliminary studies used to optimize the FG
assay revealed that using 5000 cells/well resulted in
a consistent and easily measurable difference between
the negative control and cytokine containing FG.
ECs were plated in media devoid of FGF-1 and
heparin (M-199, 10% FBS, penicillin, and strepto-
mycin). SMCs were plated in SMC growth media
(DMEM, 10% FBS, L-sodium pyruvate, L-nonessen-
tial amino acids, penicillin, streptomycin, and gen-
tamicin). Media was placed on the FG for 24 hours
and removed before plating cells to minimize the
effect of soluble FGF-1 and heparin known to be
released in the first 24 hours (delayed plating).
Additional groups of SMCs were also plated 1 hour
after the FG was made (immediate plating) to repro-
duce the inhibition on SMC proliferation by 500
U/mL heparin in the FG that was reported in the
previously published papers.5,7
After plating, the cells were allowed to grow for
48 hours, then 1 m Ci/well 3H-thymidine (NEN Life
Sciences Products) was added, and the plates were
processed 24 hours later. 3H-heparin, which was
used in the release studies, was not used at any time
during the proliferation assays. The plates were
processed by removing the media and washing the
wells with 0.9% saline. The cells were fixed in 100%
methanol (Fischer Scientific, Fair Lawn, NJ) for 10
minutes, lysed with distilled water, and the DNA was
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precipitated with 5% trichloroacetic acid. The cell
lysates were washed with distilled water, and the FG
was solubilized by adding 100 m L of 0.3 mol/L
NaOH (Sigma Chemical) and heating at 60°C for
35 minutes. This solution was placed into 10 mL
scintillation fluid that contained 20 m L acetic acid
(Fischer Scientific) to avoid opacification of the scin-
tillation fluid with an accompanying dampening of
the counts per minute (CPM).
During preliminary experiments, we found that
the FG itself has a very high background that was
not affected by the composition of the FG and
exhibited very little variance. Therefore, every plate
contained wells with FG but no cells, and the aver-
age of these wells was subtracted from the CPM of
the test wells to eliminate the high FG background.
Cells plated on FG with no additives were also
placed on each plate as a negative control, and the
data were normalized by dividing the CPM of each
well by the average of the negative control wells and
multiplying by 100%:
% of negative control = ([CPM-BKGave]/
[negative control average CPM-BKGave])100%
The data are expressed as the mean percentage of
the negative control plus or minus standard devia-
tion. All proliferation experiments were performed in
duplicate, and each treatment had 6 replicates in each
experiment (n = 12 for the combined data). After
normalizing the data from each experiment, the
observations from the two experiments were com-
bined to calculate the mean of the percentage of the
negative control plus or minus standard deviation.
Statistics. Analysis of variance with Fischer’s
Least Square Differences was used as an adjunct test,
and unpaired Student t tests were performed. The
results for these tests were reported as significant at
the P < .05 level.
RESULTS
Release of 125I-FGF-1 and 3H-heparin from
fibrin glue. The results of the release of FGF-1 and
heparin from FG are indicative of a burst effect
commonly seen with matrix types of release systems.
As shown in Fig 1, 70% ± 1% of the 125I-FGF-1 in
the FG containing 5 U/mL heparin was released
into the overlying SMC media in the first 24 hours,
with minimal release occurring thereafter (66% ± 1%
at 96 hours for 5 U/mL heparin). The results were
similar for both the 5 and 500 U/mL heparin con-
centrations, suggesting that diffusive release of FGF-
1 from FG is independent of the tested heparin con-
centrations. The media used for the EC proliferation
assays was also placed in wells containing FG with
500 ng/mL 125I-FGF-1 and 5 U/mL heparin, and
these results were also similar to the release into the
SMC media (EC media 125I-FGF-1 release at 24
hours, 65% ± 1%).
With this data, we wanted to minimize the con-
centration of released, soluble FGF-1 in the media in
our in vitro assay. Noting that most of the FGF-1
release occurred within the first 24 hours, we decid-
ed to measure the amount of 125I-FGF-1 in the
media with immediate versus delayed plating. 
Both ECs and SMCs synthesize fibrinolytic sub-
stances that may potentially degrade the fibrin
matrix and thus may alter the release of 125I-FGF-1.
Therefore, we compared media only with media
containing 5000 ECs or SMCs plated in an immedi-
ate or a 24-hour delayed fashion. By using the 24-
hour delayed plating, we hoped to decrease the
amount of soluble 125I-FGF-1 in the media. SMCs,
ECs, or media only (no cells) were plated on FG
containing 500 ng/mL 125I-FGF-1 with 5 U/mL
heparin in an immediate and delayed (media
changed 24 hours after FG polymerization) fashion
for 72 hours to determine the percent release of
Fig 1. Release of 125I-fibroblast growth factor-1 (FGF-1)
from fibrin glue (FG) into the media. The media was
placed on FG containing 500 ng/mL 125I-FGF-1 with
heparin at a concentration of 5 or 500 U/mL, and the
release of 125I-FGF-1 was serially measured at 1, 4, 8, 24,
48, 72, and 96 hours. The data are expressed as mean ±
standard deviation of percentage of FGF-1 in the media.
N = 4 for each observation. Error bars not seen indicate
standard deviation less than 1%.
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FGF-1 into the media with the two methods of plat-
ing. The cell type or absence of cells did not affect
FGF-1 release, but there was five times more FGF-1
in the media for the immediate versus delayed plat-
ing (P < .001; Fig 2).
After counting, all the medias underwent precipi-
tation experiments to determine the percentage of 125I
that was bound to the FGF-1. The mean percentage
bound for the entire experiment was 93% ± 3%.
The results for 5 U/mL 3H-heparin release from
FG were comparable with the 125I-FGF-1 diffusive
release. At 24 hours, 59% ± 2% 3H-heparin was
released, with minimal release thereafter (67% ± 1%
at 96 hours). There was no significant difference in
3H-heparin release into EC or SMC media. The
addition of FGF-1 at 10 or 1000 ng/mL concentra-
tions had a minimal effect on the release of 3H-
heparin (59% ± 2% and 67% ± 2% at 24 hours for
FGF-1 at 10 and 1000 ng/mL concentrations,
respectively; Fig 3).
There was a significantly higher percentage of
3H-heparin released at a concentration of 500
U/mL than at one of 5 U/mL (P < .001 for both
the 24- and 96-hour time points). Release at the 500
U/mL concentration was 80% ± 1% at 24 hours and
97% ± 1% at 96 hours. This is thought to be poten-
tially related to artifact. There were difficulties in
measuring the CPM of the 500 U/mL 3H-heparin,
because the CPM of these samples was initially too
high to measure. Serial dilutions of these samples
were performed until they could be counted. This
may have led to differences in counting efficiency.
This potential artifact may have especially affected
the total counts measured in the 30 m L of FG that
was initially placed into 10 mL of scintillation fluid
(the denominator), thus leading to lower total
counts and, therefore, a higher percent released.
SMCs or media only (no cells) were plated on
FG containing 5 U/mL 3H-heparin in an immediate
or a delayed fashion. The presence or absence of
cells did not affect heparin release, but there was
four times more heparin in the media for the imme-
diate versus the delayed plating (P < .001; Fig 4).
Endothelial cell and smooth muscle cell pro-
Fig 2. Effect of immediate versus delayed plating on release
of 125I-fibroblast growth factor-1 (FGF-1) from fibrin glue
(FG). Cells were plated on FG containing 500 ng/mL 125I-
FGF-1 with 5 U/mL heparin in an immediate or in a 24-
hour delayed fashion, and the release of 125I-FGF-1 into the
media was measured 72 hours after the cells were plated. The
data are expressed as mean ± standard deviation of percent-
age 125I-FGF-1 in the media. N = 4 for each observation.
SMC, Smooth muscle; EC, endothelial cell.
Fig 3. Release of 3H-heparin from fibrin glue (FG) into
the media. Media was placed on FG containing 5 or 500
U/mL 3H-heparin, either alone or in combination with
10 or 1000 ng/mL fibroblast growth factor-1 with 5
U/mL 3H-heparin, and the release of 3H-heparin was
serially measured at 4, 24, 48, and 96 hours. The data are
expressed as mean ± standard deviation of percentage of
heparin in the media. N = 3 for each observation.
liferation assays, delayed plating. Delayed plating
of ECs and SMCs was performed on FG to mini-
mize the effect of the release of FGF-1 and heparin
that occurs within the first 24 hours. This is an
important point, because substances released from
FG in vivo will be removed by blood flow and thus
may not exert a local effect. Substances released
from FG in vitro will be soluble in the overlying
media and, if the media is not removed before cell
plating, can thereby affect SMC and EC prolifera-
tion. The data for both EC and SMC proliferation
assays are shown in Table I. We did not test FG with
FGF-1 in the absence of heparin caused by our two
previous studies,5,8 which showed that FGF-1 alone
in the FG did not induce any significantly greater
proliferation than the negative control.
EC proliferation assays on FG containing FGF-1
concentrations of 0, 10, 100, or 1000 ng/mL and
heparin concentrations of 0, 5, 50, or 500 U/mL
revealed that the lowest tested FGF-1 concentration
that produced a maximal proliferative effect occurred
at 100 ng/mL FGF-1 and 5 U/mL heparin (all with
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5 U/mL heparin; P < .0001 for 100 mg/mL FGF-1
versus 10 mg/mL FGF-1, and P = .16 for 100
ng/mL FGF-1 versus 1000 ng/mL FGF-1). As the
heparin dose increased to 50 U/mL, EC proliferation
decreased, and at 500 U/mL, canine jugular ECs
died. Previous experiments have shown that FG that
contains FGF-1, in the absence of heparin, does not
induce EC or SMC proliferation higher than control
levels, because the thrombin in the FG degrades the
FGF-1, thereby inactivating it.5,8
Heparin doses as high as 500 U/mL had little
effect on SMC proliferation when cells were plated
in a delayed fashion on FG containing FGF-1. In the
absence of FGF-1, there was a trend for decreased
SMC proliferation with increasing heparin in the
FG, but these differences were not statistically sig-
nificant (P = .065 for 5 U/mL heparin versus 500
U/mL heparin). Similar to the ECs, FGF-1 at a con-
centration of 100 ng/mL gave a maximal prolifera-
tive effect (no significant difference between 100
ng/mL FGF-1 and 1000 ng/mL for the heparin 50
and 500 concentrations; P < .001 for 100 ng/mL
FGF-1 versus 1000 ng/mL for the 5 U/mL heparin
concentration; P < .0001 for 10 ng/mL FGF-1 ver-
sus 100 ng/mL for all three heparin concentra-
tions). 
Smooth muscle cell proliferation assays,
immediate plating. As shown in Table II, heparin
at a 500 U/mL concentration inhibited SMC pro-
liferation, as compared with concentrations of 5 or
50 U/mL, when immediate plating was used (P <
.001 for all three doses of FGF-1 when comparing
the 5 U/mL heparin versus the 500 U/mL heparin
concentration). Heparin at a 50 U/mL concentra-
tion inhibited SMC proliferation when 10 ng/mL
FGF-1 was present, as compared with FG containing
10 ng/mL FGF-1 and 5 U/mL heparin (P < .01).
As the FGF-1 dose increased to 100 and 1000
ng/mL, the FGF-1 overcame the effect of the
heparin, and there was no significant difference in
SMC proliferation at these two FGF-1 doses when
comparing heparin at concentrations of 5 or 50
U/mL. The inhibition of SMC proliferation with
increasing heparin dose is likely caused by the solu-
ble, released heparin at 24 hours. By means of the
radioactive heparin release data, the heparin concen-
tration in the media would be approximately 45
U/mL, which is a high enough concentration to
inhibit SMC proliferation.8 Comparing immediate
versus delayed plating at equivalent FGF-1 and
heparin concentrations, immediate plating induced
greater proliferation than delayed plating, likely
because of the higher soluble FGF-1 concentration.
Fig 4. Effect of immediate versus delayed plating on
release of 3H-heparin from fibrin glue (FG). Cells were
plated on FG containing 5 U/mL 3H-heparin in an imme-
diate or in a 24-hour delayed fashion, and the release of
3H-heparin into the media was measured 72 hours after
the cells were plated. The data are expressed as mean ±
standard deviation of percentage of 3H-heparin in the
media. N = 3 for each observation.
SMC, Smooth muscle cell.
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DISCUSSION
FG has many applications,9 including hemostasis
in surgery10,11 and thermal burns12 and as a carrier
for antibiotics13 and chemotherapeutic agents,14 in
addition to its uses as a surface coating for vascular
grafts3,4,15 and angioplasty sites.6 FGF-1 was chosen
for its strong chemoattractant and mitogenic activi-
ty for ECs and its relatively weak SMC mitogenic
activity. In the absence of heparin, FGF-1 induces
minimal SMC proliferation. With the addition of
small amounts of heparin, SMC proliferation dra-
matically increases. The addition of heparin, howev-
er, is necessary in FG to protect FGF-1 from throm-
bin-induced cleavage.8 Previous reports5,7 have used
multiple concentrations of cytokines and heparin in
FG in in vitro tissue culture models to optimize FG
systems for use in animal models. Both of these
papers found that high heparin concentrations (500
U/mL) in the FG inhibited SMC proliferation, but
did not affect EC proliferation. These studies used
immediate plating of cells and thus were affected by
the soluble factors that are released from the FG. We
have found that 70% ± 1% of FGF-1 and 59% ± 2%
of heparin is released from the FG within the first 24
hours. To assess the effect of this release on cell
growth, we placed media in the wells for 24 hours,
and then removed the media before plating the cells
(delayed plating). There was five times more 125I-
FGF-1 and four times more 3H-heparin in the media
of the immediate, as compared with the delayed,
plating conditions, and the presence or absence of
cells had minimal effects on the release of these sub-
stances from the FG. The data for the release of 3H-
heparin from FG at the 500 U/mL concentration
showed a higher percentage (80% ± 1%) than the 5
U/mL concentration (59% ± 2%) at 24 hours. There
were methodological difficulties with measuring the
release of the 500 U/mL concentration, because the
FG was too hot to count accurately. 
Quantifying the release of substances from FG is
important for designing in vitro assays that may bet-
ter predict the effect of the FG composition in vivo.
One must be careful, however, not to extrapolate
the in vitro release data to in vivo situations and dif-
ferent surfaces. In vivo rabbit studies with radio-
labeled FGF-1 in FG impregnated onto ePTFE aor-
tic interposition grafts revealed 45.1% ± 5.7%, 19.5%
± 1.6%, and 5.4% ± 0.2% retention after 5 minutes,
60 minutes, and 7 days, respectively.16 By using a
carotid balloon-injury model in dogs,6 we studied
the percentage retention of 125I-FGF-1 in FG on the
injured arterial surface. After 10 minutes of arterial
circulation, there was 41% retention of 125I-FGF-1
and 37.4% ± 12.2% after 60 minutes (no significant
difference between the two time points).
By using the 24-hour in vitro release data, we
then altered our proliferation assay to minimize the
effect of the soluble substances on cellular prolifera-
tion by placing growth media on the FG for 24
hours before plating the cells. When plated in a
delayed fashion, heparin at concentrations as high as
500 U/mL in the FG did not inhibit SMC prolifer-
ation. We then performed our assay with immediate
plating of SMCs to see if the heparin inhibition of
SMC proliferation reported by Kang et al5 and
Weatherford et al7 could be reproduced. Heparin at
a concentration of 500 U/mL in the presence of
FGF-1 at 10, 100, or 1000 ng/mL again inhibited
SMC proliferation, as compared with 5 U/mL
heparin (P < .001 for all three FGF-1 concentra-
tions). Comparing immediate versus delayed SMC
plating, at equivalent FGF-1 and heparin doses,
Table I. Endothelial cell (EC) and smooth muscle cell (SMC) proliferation on fibrin glue (FG) plated in a
delayed fashion. SMCs or ECs were plated on FG containing fibroblast growth factor-1 (FGF-1) and
heparin 24 hours after the FG was made to exclude the effect on cell growth of the initial release of FGF-1
and heparin into the media. The data are presented as the percent of the negative control (FG with no
heparin or FGF-1). N = 12 for each observation.
EC proliferation (% control) SMC proliferation (% control)
U/mL heparin 5 50 500 5 50 500
No cytokine 115 ± 3 86 ± 6 26 ± 30 118 ± 12 99 ± 21 78 ± 20
10 ng/mL FGF-1 144 ± 7*† 107 ± 8* 15 ± 12 156 ± 15† 193 ± 28* 161 ± 18*
100 ng/mL FGF-1 220 ± 14*† 116 ± 7* 52 ± 91 325 ± 59*† 392 ± 30* 367 ± 37*
1000 ng/mL FGF-1 228 ± 12* 124 ± 7* 10 ± 10 408 ± 38* 393 ± 27* 379 ± 45*
*P < .01 versus same heparin dose with no cytokine.
†P < .0001 for 10 ng/mL FGF-1 versus 100 ng/mL FGF-1 with 5 U/mL heparin for both ECs and SMCs.
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immediate plating induced greater proliferation than
delayed plating (P < .001 for all FGF-1 and heparin
combinations tested). As seen with the radio-labeled
release experiments, immediate versus delayed plat-
ing resulted in five times more 125I-FGF-1 and four
times more 3H-heparin in the media of the immedi-
ate plating. SMCs are very sensitive to soluble
heparin and FGF-1 in the media. FGF-1 concentra-
tions as low as 1 ng/mL with 5 U/mL heparin in
the media can induce significant proliferation.
Heparin at a concentration of 50 U/mL significant-
ly decreases SMC proliferation in the presence of
FGF-1, as compared with 5 U/mL heparin when
both factors are soluble in the media. Heparin at a
concentration of 500 U/mL in the media reduces
SMC proliferation to baseline levels, even in the
presence of 10 ng/mL FGF-1.8 By using the radio-
labeled data for immediate versus delayed plating to
estimate the concentration of FGF-1 and heparin in
the media caused by diffusive release, at the 100
ng/mL FGF-1 and 500 U/mL heparin doses in FG,
the concentration of FGF-1 in the media would be
15 and 70 ng/mL in the delayed and immediate
plating media, respectively. Heparin concentrations
would be 70 and 295 U/mL in the delayed and
immediate plating media, respectively. These con-
centration differences can explain the discrepancy
between the heparin effect on SMC proliferation
when immediate and delayed plating are used. We
cannot entirely exclude, however, the effect of solu-
ble FGF-1 in the media, even with the delayed
method of plating. In vivo release data of substances
from FG are different than the in vitro release data
presented in the current work. In vivo, substances
released from FG will diffuse into the blood vessel
lumen and will be locally removed by blood flow.
Diffusive loss will also occur in the vessel or graft
wall FG impregnation setting.
EC proliferation with delayed plating revealed
rather surprising results in comparison with the two
earlier studies. In the current study, 50 U/mL
heparin in the FG in the presence of FGF-1 inhibit-
ed EC proliferation, as compared with 5 U/mL
heparin. As the heparin increased to 500 U/mL, the
ECs died. In contrast, Weatherford et al7 demon-
strated that the addition of 50 U/mL heparin in FG
enhanced EC proliferation (immediate plating) in
the presence of VEGF, as compared with FG con-
taining VEGF alone. Data for 500 U/mL heparin in
FG were not shown in this paper for ECs. Kang et
al5 found that heparin at concentrations as high as
500 U/mL in the FG did not affect EC proliferation
(immediate plating). The soluble heparin concentra-
tion in the Kang et al5 study would be higher than
in the current study because of the differences
induced by immediate versus delayed cell plating.
Perhaps these discrepancies can be explained by the
cell types used in these three studies, which may
reflect differences in response by ECs of different
species or of different vascular beds. Weatherford et
al7 used human aortic ECs, and Kang et al5 used
HUVECs, whereas we used canine jugular vein ECs.
We chose canine jugular vein ECs because we have
previously seeded this cell type contained within FG
onto balloon-injured canine carotid arteries.6 Also,
we wanted to use canine ECs because our in vivo
model is in the dog. We can merely speculate on the
differences reported from these three studies,
because the data presented in this paper provide no
clear answers to these questions. Perhaps the dis-
crepancy in the three papers is caused by differences
in the types of heparin used or differences in human
Table II. Smooth muscle cell proliferation on fibrin glue plated in an immediate fashion. The data are pre-
sented as the percent of the negative control (fibrin glue with no heparin or fibroblast growth factor-1). N
= 12 for each observation.
Immediate plating: SMC proliferation (% control)
U/mL heparin 5 50 500
No cytokine 109 ± 10† 98 ± 14‡ 35 ± 23†‡
10 ng/mL FGF-1 498 ± 70*† 421 ± 55* 352 ± 24*†
100 ng/mL FGF-1 598 ± 120*† 585 ± 114* 460 ± 22*†
1000 ng/mL FGF-1 571 ± 106*† 573 ± 102* 450 ± 33*†
*P < .01 versus same heparin dose with no cytokine.
†P < .001 for 5 U/mL heparin versus 500 U/mL heparin with the same fibroblast growth factor-1 concentration.
‡P < .04 for 50 U/mL heparin versus 500 U/mL heparin.
SMC, smooth muscle cell; FGF-1, fibroblast growth factor-1.
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versus canine ECs. Alternatively, differences in
venous versus arterial ECs may also play a role.
HUVECs contain fetal components, and thus, this
cell line does not always respond the same as adult
ECs. We are currently culturing canine arterial ECs
to see if the arterial ECs also display the same
heparin sensitivity exhibited by the venous canine
ECs. Thus, the results of this study vary significant-
ly from the two earlier studies because of immediate
versus delayed plating, differences in the heparin
used, and differences in the cells used. 
It is difficult to differentiate growth inhibition
from cell death. We did not assay lactate dehydroge-
nase or other markers of cell death. However, neither
SMC or EC death has been reported from FGF-1 or
heparin in the concentrations used. Morphologically,
the cells appeared intact, and minimal cellular debris
or desquamation was observed under phase contrast
microscopy in any experiment, with the exception of
the ECs exposed to 500 U/mL heparin, in which cell
loss and cellular debris were visible.
This study highlights the importance of the
release of substances from FG and the importance of
species differences when designing in vitro assays.
For in vivo use in the dog model, this report sup-
ports the use of low heparin concentrations (5
U/mL) in the FG. The concentration of FGF-1
should be high enough to still be effective after the
initial, large release of FGF-1 exhibited by both in
vitro and in vivo6,16 studies. Further experiments
studying the release of radioactive FGF-1 from FG
in the in vivo dog model are needed to address the
issue of FGF-1 concentration. This, however, still
does not address the issue of capsular thickening
seen in the report by Gray et al4 and the concerns
about intimal hyperplasia induced by the FGF-1
proliferative effect on SMCs. By using site-directed
mutagenesis, we are currently exploring the effect of
different FGF-1 mutants on EC and SMC prolifera-
tion. We hope to discover a mutant that will prefer-
entially stimulate EC proliferation while inhibiting,
or at least not enhancing, SMC proliferation.
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Dr Joseph Schneider (Evanston, Ill). I am intrigued
by the bioengineering question of how long it would take
these cytokines to elute from a graft or denuded artery in
vivo and how that compares with the amount of time the
material needs to be around in the petri dish to have a
beneficial effect. Could it be around long enough to have
a local beneficial effect in vivo?
Dr Paula Shireman. The kinetics of cellular prolifera-
tion in vitro are very different than in vivo proliferation.
In vitro, the greatest amount of proliferation in this
mold occurs 24 to 72 hours after plating, and then prolif-
eration decreases because of contact inhibition. In vivo
kinetics would theoretically be different, because you are
dealing with a denuded artery after an angioplasty or a graft
surface in which contact inhibition would probably not
occur within the first 72 hours. So, there are kinetic differ-
ences, and certainly we’ve not looked at what length of
time is important for the fibroblast growth factor-1 (FGF-
1) to be present. Whether a pulse dose of FGF-1 within the
first hour with subsequent removal would cause similar
proliferation versus having the FGF-1 there constantly,
which is essentially what is happening in our model, has not
been investigated by our laboratory. With the fibrin glue,
our thought is that it’s a slow-release type of system, which
keeps the cytokine there longer than if you merely put the
cytokine onto a graft site or into the media. And so, that’s
one of the reasons we’ve tried to use fibrin glue as a
cytokine-release system, in an attempt to try to re-endothe-
lialize denuded arteries and prosthetic grafts.
Dr William Turnipseed (Madison, Wis). I have a cou-
ple of questions. First, are there any kinetics for subset
release that would be different in an in vitro, as opposed
to an in vivo, model?
Second, were you aware of the species differentiation
of response to heparin between the canine and human
models? If so, why didn’t you do this with human cells? 
Dr Shireman. Those are two very good questions. I
will answer the question about heparin effect on different
types of endothelial cells first.
We were surprised by this too, because previous reports
in the literature have used enough heparin to augment
FGF-1 or whatever cytokine they were studying, which
requires relatively low doses of heparin. I do not think
there have been many studies that have looked at heparin
toxicity in relation to endothelial cells, and not many peo-
ple have looked at high heparin concentrations. The reason
we were initially interested in high heparin concentrations
was as a way to inhibit smooth muscle cells and yet not
decrease the endothelial cell proliferation. The original
studies that we did were on human umbilical vein endothe-
lial cells, which are sort of a renegade breed of endothelial
cells. We used them because they are readily available and
easy to grow, but I am not sure that the response of the
human umbilical vein endothelial cells really reflects what
will happen in human or other animal models.
Why does heparin inhibit canine jugular vein endothe-
lial cell proliferation? I don’t know. It could be that there
is something added to the heparin during processing that
is actually inhibitory to the endothelial cell. Endothelial
cells make heparinoids. But maybe too much of a good
thing is not always better, and there appear to be toxic lev-
els. Whether this reflects a venous versus an arterial differ-
ence or a human versus a canine difference, I’m not sure,
and of all the observations that have come from this paper,
that might be the most interesting question to chase.
About the question regarding the difference between
in vivo and in vitro release kinetics: We do have some data
that has been accumulated in our laboratory measuring in
vivo release of radioactive FGF-1. In a rabbit model with
polytetrafluoroethylene grafts coated with 125I-FGF-1 in
fibrin glue implanted into the aorta, exposed to blood
flow, and removed at different time points, the percentage
retention of FGF-1 on the graft was 45% ± 5.7%, 19.5% ±
1.6%, and 5.4% ± 0.2% at 5 minutes, 60 minutes, and 7
days, respectively. If you compare that with the in vitro
data, after 24 hours, 70% of the FGF-1 has been released
into the media. So, certainly the FGF-1 may have some
binding kinetics to the arterial lining or to the polytetra-
fluoroethylene grafts that we are not seeing in the in vitro
fibrin glue kinetic studies.
DISCUSSION
